Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

A college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...